LFCR — Lifecore Biomedical Share Price
0.000.00%
Last trade - 00:00- $236.22m
- $355.74m
- $128.26m
- 52
- 36
- 97
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.98 | ||
| Price to Tang. Book | 8.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.89% | ||
| Return on Equity | -110.05% | ||
| Operating Margin | -15.67% | ||
Financial Summary
| Year End 26th May | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 160.07 | 100.87 | 111.27 | 103.27 | 128.26 | 127.72 | 132.8 | -25.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Directors
- Craig Barbarosh NEC (53)
- Albert Bolles PRE (63)
- John Morberg CFO (55)
- James Hall VPR (58)
- Deborah Carosella IND (64)
- Jeffrey Edwards IND (61)
- Katrina Houde IND (62)
- Nelson Obus IND (74)
- Tonia Pankopf IND (53)
- Andrew Powell IND (63)
- Joshua Schechter IND (48)
- Catherine Sohn IND (68)
- Last Annual
- May 26th, 2024
- Last Interim
- February 23rd, 2025
- Incorporated
- August 22nd, 2007
- Public Since
- February 15th, 1996
- No. of Shareholders
- 46
- No. of Employees
- 524
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 37,025,331
- Address
- 3515 Lyman Boulevard, CHASKA, 55318
- Web
- https://www.lifecore.com/
- Phone
- +1 9523684300
- Contact
- Stephanie Diaz
- Auditors
- BDO USA, P.C.
Upcoming Events for LFCR
Q1 2026 Lifecore Biomedical Inc Earnings Release
Similar to LFCR
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Lifecore Biomedical share price?
As of Today at 21:45 UTC, shares in Lifecore Biomedical are trading at $6.38. This share price information is delayed by 15 minutes.
How has the Lifecore Biomedical share price performed this year?
Shares in Lifecore Biomedical last closed at $6.38 and the price had moved by -3.92% over the past 365 days. In terms of relative price strength the Lifecore Biomedical share price has underperformed the S&P500 Index by -11.31% over the past year.
What are the analyst and broker recommendations for Lifecore Biomedical?
The overall consensus recommendation for Lifecore Biomedical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lifecore Biomedical dividend yield?
Lifecore Biomedical does not currently pay a dividend.
Does Lifecore Biomedical pay a dividend?
Lifecore Biomedical does not currently pay a dividend.
When does Lifecore Biomedical next pay dividends?
Lifecore Biomedical does not currently pay a dividend.
How do I buy Lifecore Biomedical shares?
To buy shares in Lifecore Biomedical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lifecore Biomedical?
As of the previous close price of $6.38, shares in Lifecore Biomedical had a market capitalisation of $236.22m.
Where are Lifecore Biomedical shares listed?
Here are the trading details for Lifecore Biomedical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LFCR
What kind of share is Lifecore Biomedical?
Based on an overall assessment of its quality, value and momentum Lifecore Biomedical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lifecore Biomedical share price forecast for 2025?
The analyst consensus target price for shares in Lifecore Biomedical is $10.00. That is 56.74% above the last closing price of $6.38.
Analysts covering Lifecore Biomedical currently have a consensus Earnings Per Share (EPS) forecast of -$1.33 for the next financial year.
Find out moreWhat is the trend in the Lifecore Biomedical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lifecore Biomedical. Over the past six months, its share price has outperformed the S&P500 Index by +22.37%.
As of the last closing price of $6.38, shares in Lifecore Biomedical were trading +6.57% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lifecore Biomedical PE Ratio?
The Lifecore Biomedical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lifecore Biomedical?
Lifecore Biomedical's management team is headed by:
- Craig Barbarosh - NEC
- Albert Bolles - PRE
- John Morberg - CFO
- James Hall - VPR
- Deborah Carosella - IND
- Jeffrey Edwards - IND
- Katrina Houde - IND
- Nelson Obus - IND
- Tonia Pankopf - IND
- Andrew Powell - IND
- Joshua Schechter - IND
- Catherine Sohn - IND